Compare iShares MSCI France ETF (EWQ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Natera Inc. Common Stock — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $332.79M), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 171.4× iShares MSCI France ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 57 Days and Natera Inc. Common Stock for 0 Days on average.
| EWQ | NTRA | |
|---|---|---|
Market Cap | $332.79M | $57.03B |
Volume | 668,920 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $425.64 |
52-Week Low | $41.24 | $179.42 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.63, up 0.95% with a bearish technical signal from moving averages. The stock faces European market pressures including ECB rate hikes and energy-driven inflation concerns. Key support sits at $41 with resistance at $42, while RSI indicators show mixed signals between neutral and oversold conditions.
European economic uncertainty and monetary tightening create headwinds, though Goldman Sachs notes resilience in European equities. The stock's technical weakness suggests cautious near-term positioning amid macroeconomic volatility in eurozone markets.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
